BRCA1 and breast carcinoma: This is the basis for the concept that PARP inhibitors induce synthetic lethality in HR repair deficient tumors and provides a novel strategy for cancer therapy, at least in breast cancer patients who have mutations in BRCA1 or BRCA2.